Published on in Vol 2, No 3 (2021): Jul-Sep
Preprints (earlier versions) of this paper are
available at
https://www.medrxiv.org/content/10.1101/2021.04.09.21255219v1, first published
.
![Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study](https://asset.jmir.pub/assets/8d099cbcf5e518e24f047c9a882f2313.png 480w,https://asset.jmir.pub/assets/8d099cbcf5e518e24f047c9a882f2313.png 960w,https://asset.jmir.pub/assets/8d099cbcf5e518e24f047c9a882f2313.png 1920w,https://asset.jmir.pub/assets/8d099cbcf5e518e24f047c9a882f2313.png 2500w)
1 Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hofstra University, Hempstead, NY, United States
2 Northwell Health, New Hyde Park, NY, United States
*all authors contributed equally